I find it concerning that BRN continues to emphasize a COVID19 breathalyzer as the first commercial breakthrough application at the same time as massive amounts of vaccines are manufactured every day, and mass testing becomes available for very little cost in various places, meaning that in a few weeks life will pretty much return to normal and there will be no meaningful economics to such a product.
Even if the product was available today - which it is not - I am doubtful about its economic viability.
BRN should focus on areas where it can make a real difference, with solutions others cannot offer (yet).
Less podcasts, more tangible commercial successes.
2021 BRN Discussion, page-371
-
- There are more pages in this discussion • 33,210 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BRN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
-0.005(2.33%) |
Mkt cap ! $389.7M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 20.8¢ | $610.1K | 2.904M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 593140 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 560405 | 10 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| BRN (ASX) Chart |